Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Kreitman Website

Robert J. Kreitman, M.D.

Selected Links

•  Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia - Relapsed Hairy Cell Leukemia, Multicenter Immunotherapy Non-Placebo Phase 3 Trial
•  Cladribine and Rituximab for Early Hairy Cell Leukemia - Trial using rituximab to prevent relapse in early hairy cell leukmeia
•  Study of Ibrutinib for Treatment of Relapsed Hairy Cell Leukemia - For patients with relapsed hairy cell leukemia (HCL), including HCL variant
•  Phase II trial of LMB-2 after fludarabine and cyclophosphamide for adult T-cell leukemia - For patients with adult T-cell leukemia to target the ATL cells, using FC chemotherapy to prevent antibodies and improve the chance for complete remission
•  Randomized trial of rituximab with either bendamustine or pentostatin for hairy cell leukemia - Patients who have had multiple prior treatments for HCL
•  LMB-2 to Treat Hairy Cell Leukemia - A non-chemotherapy option for patients with hairy cell leukemia who are not eligible for Moxetumomab Pasudotox
•  LMB trials at NIH - LMB trials at NIH, NCI
•  Moxetumomab Pasudotox Info - Information regarding the Phase 3 Pivotal trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
•  Moxetumomab Pasudotox trial letter - Letter to physicans

This page was last updated on 3/26/2014.